Zynex (NASDAQ:ZYXI) Issues Earnings Results, Misses Expectations By $0.04 EPS

Zynex (NASDAQ:ZYXI) issued its earnings results on Thursday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04), Briefing.com reports. Zynex had a return on equity of 16.34% and a net margin of 4.33%. The company had revenue of $49.88 million for the quarter, compared to analyst estimates of $51.99 million. During the same quarter in the previous year, the company posted $0.09 earnings per share. The company’s quarterly revenue was up 11.0% compared to the same quarter last year.

Zynex Trading Down 12.4 %

Shares of Zynex stock traded down $1.26 during trading hours on Friday, reaching $8.93. 1,034,596 shares of the company’s stock were exchanged, compared to its average volume of 195,244. The firm has a market capitalization of $283.75 million, a price-to-earnings ratio of 38.83 and a beta of 0.53. The company has a current ratio of 3.58, a quick ratio of 2.87 and a debt-to-equity ratio of 1.76. Zynex has a 52-week low of $6.88 and a 52-week high of $13.77. The company has a fifty day moving average of $9.55 and a 200-day moving average of $11.06.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ZYXI. Royal Bank of Canada cut their target price on shares of Zynex from $15.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday. HC Wainwright cut their target price on shares of Zynex from $21.00 to $16.00 and set a “buy” rating for the company in a research note on Friday.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.